---
schema_version: "secwatch.filing_event.v1"
accession: "0001479681-25-000008"
form_type: "8-K"
ticker: "NUTX"
cik: "0001479681"
company_name: "Nutex Health Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:42:10.287901+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nutex Health reports FY 2024 net income of $52.2M vs loss of $45.8M in 2023; revenue up 93.8% to $479.9M

## Summary
- FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.
- Diluted EPS $9.71 vs $(10.39); Adjusted EBITDA $123.7M up 1,045% from $10.8M.
- Arbitration process added $169.7M more revenue in 2024 than 2023; drove 73.1% of revenue growth.
- Q4 2024 revenue $257.6M (+270% YoY); operating income $114.2M vs operating loss $26.1M.
- Cash from ops $23.2M; total assets $655.3M; long-term debt $22.5M.

## SEC filing metadata
- accession: 0001479681-25-000008
- form_type: 8-K
- ticker: NUTX
- cik: 0001479681
- company_name: Nutex Health Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/0001479681-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/nutx-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001479681-25-000008
- JSON: https://secwatch.observer/filing/0001479681-25-000008.json
- Plain text: https://secwatch.observer/filing/0001479681-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.